GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Revenue

IRLAB Therapeutics AB (OSTO:IRLAB A) Revenue : kr5.68 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Revenue?

IRLAB Therapeutics AB's revenue for the three months ended in Mar. 2024 was kr0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr5.68 Mil. IRLAB Therapeutics AB's Revenue per Share for the three months ended in Mar. 2024 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.11.

During the past 12 months, the average Revenue per Share Growth Rate of IRLAB Therapeutics AB was -89.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 11 years, IRLAB Therapeutics AB's highest 3-Year average Revenue per Share Growth Rate was 956.70% per year. The lowest was -45.00% per year. And the median was 14.50% per year.


IRLAB Therapeutics AB Revenue Historical Data

The historical data trend for IRLAB Therapeutics AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Revenue Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 - 207.78 61.14 5.68

IRLAB Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.87 - -1.19 -

Competitive Comparison of IRLAB Therapeutics AB's Revenue

For the Biotechnology subindustry, IRLAB Therapeutics AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Revenue distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Revenue falls into.



IRLAB Therapeutics AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


IRLAB Therapeutics AB Revenue Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Traded in Other Exchanges
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines